within Pharmacolibrary.Drugs.ATC.J;

model J01DC02
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 5e-05,
    adminDuration  = 600,
    adminMass      = 750 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.009300000000000001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0074,
    k12             = 6.1,
    k21             = 6.1
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J01DC02</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Cefuroxime is a second-generation cephalosporin antibiotic with broad-spectrum activity against gram-positive and gram-negative bacteria. It is used to treat various infections, including respiratory tract, urinary tract, skin and soft tissue infections. Cefuroxime is approved and widely used clinically.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers after a single intravenous dose.</p><h4>References</h4><ol><li><p>Thønnings, S, et al., &amp; Frimodt-Møller, N (2020). Cefuroxime pharmacokinetics and pharmacodynamics for intravenous dosage regimens with 750 mg or 1500 mg doses in healthy young volunteers. <i>Journal of medical microbiology</i> 69(3) 387–395. DOI:<a href=&quot;https://doi.org/10.1099/jmm.0.001138&quot;>10.1099/jmm.0.001138</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31958049/&quot;>https://pubmed.ncbi.nlm.nih.gov/31958049</a></p></li><li><p>Foord, RD (1976). Cefuroxime: human pharmacokinetics. <i>Antimicrobial agents and chemotherapy</i> 9(5) 741–747. DOI:<a href=&quot;https://doi.org/10.1128/AAC.9.5.741&quot;>10.1128/AAC.9.5.741</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/949172/&quot;>https://pubmed.ncbi.nlm.nih.gov/949172</a></p></li><li><p>Gower, PE, &amp; Dash, CH (1977). The pharmacokinetics of cefuroxime after intravenous injection. <i>European journal of clinical pharmacology</i> 12(3) 221–227. DOI:<a href=&quot;https://doi.org/10.1007/BF00609865&quot;>10.1007/BF00609865</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/590309/&quot;>https://pubmed.ncbi.nlm.nih.gov/590309</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J01DC02;
